Prospective Data Collection Initiative on Thoracic Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

12000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-15

Study Completion Date

2030-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Survival after cancer diagnosis strongly depends on local tumor extent, lymph node involvement and the presence of distant metastases. However, there remains great inter-patient variability regarding treatment outcome. A combination of molecular factors, biochemical factors, histopathological features, genomic profile, environmental factors and other clinical factors are likely to influence prognosis and treatment effect, independent from tumor stage. It is however still unclear which, how, and to what extent these factors will influence tumor recurrence and mortality in both early stage (I-III) and late stage (IV) thoracic malignancies such as lung cancer.

Although the results from prospective clinical trials will remain the backbone of evidence-based medicine, this concerns a highly selected patient population since the large majority (85%-95%) of patients with cancer do not participate in clinical trials for various reasons. It is unlikely that trial participation will significantly improve in the near future. This fact has the following implications:

1. It is highly desirable to validate the results from clinical trials in the general patient population. This is complicated by the fact that the documentation of patients treated in general practice (i.e. outside the scope of clinical trials) is largely insufficient to provide comparable patient cohorts in terms of prognostic characteristics and treatment parameters.
2. There is an ever increasing number of therapeutic interventions available for which its efficacy depends on known and unknown tumor-specific, clinical, demographic and other patient characteristics. Large numbers of patients are required to test the relevance of these variables.
3. As a result of rapid technical and drug developments, new minimally invasive treatment options such as stereotactic irradiation or ablation techniques or sublobar resections and new targeted and immunotherapeutic treatments have entered the clinic. These interventions have potentially less side effects compared to the conventional treatments. Still, these new interventions will have to prove their effectiveness, safety and superiority (or non-inferiority) in a real world setting.
4. Many hypotheses related to further optimization of personalized medicine can currently not be tested as they require a large prospective cohort of patients, and a less time-consuming and costly research infrastructure.

A prospective observational cohort study has the potential to fill the gap between prospective randomized trials (efficacy) and patients treated in general practice (effectiveness) and it will enable accrual of clinical trials (innovation).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab

NCT05027165

Oncology Biomarker NSCLC, Stage III +2 more

UNKNOWN

Interest of CPET to Predict Mortality and Complications of Lung Resection Candidates

NCT05502263

Exercise Test Thoracic Cancer

UNKNOWN

Thoracic Tumours Register

NCT02941458

Thoracic Tumors

RECRUITING

Metabolomics Predict Therapy Response

NCT03736993

NSCLC, Stage IIIA

COMPLETED NA

Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma

NCT06833229

Carcinoma, Non-Small-Cell Lung (NSCLC)

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective:

* To start a prospective observational cohort study of patients with thoracic malignancies from their primary diagnosis until death.
* After obtaining informed consent, to prospectively collect data on medical history, comorbidities, baseline clinical parameters, imaging results, pathology results, tumor characteristics, treatment, treatment outcomes, hospital stays, interventions and (S)AEs.
* After obtaining separate informed consent for collecting data on health related quality of life and work ability, to collect data on patient reported outcome measures.
* After obtaining separate informed consent, to collect imaging, blood and (tumor) tissue material, obtained during routine practice, for observational studies or storage in the biobank.
* After obtaining separate informed consent, to collect imaging obtained during routine practice, for observational studies or AI learning.
* The cohort will serve as an infrastructure geared towards efficient, safe and comprehensive clinical evaluation of new interventions (for example multidisciplinary anti-cancer treatment, drugs or other systemic treatment, lifestyle or in follow up) for patients with thoracic malignancies when appropriate according to the Trials within Cohorts (TwiCs) design. For interventions other than standard of care a separate informed consent is mandatory.

Expected outcome:

* To provide more accurate data on the treatment and clinical outcome and patient reported outcomes of thoracic malignancies in daily practice.
* To create an infrastructure for a large variety of research purposes including but not limited to:

* Prognostic and predictive research
* Molecular and (epi)genetic research
* Comparison of new therapeutic interventions for patients with thoracic malignancies, when appropriate according to the Trials within Cohorts (TwiCs) design.
* Health care policies and cost-effectiveness studies

Study design:

A prospective observational cohort study. Patients diagnosed with thoracic malignancies will be asked to participate in this cohort. Prospectively, a limited number of variables (e.g. gender, age, histology, TNM) will in the majority of cases preferably be registered within 1-3 weeks following diagnosis. Further enrichment of the data will be done by linking this cohort to the Netherlands Cancer Registry (NCR) database (in the Netherlands clinical variables, treatment variables of all malignancies are routinely collected (Appendix I)) on a 6 monthly basis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Thoracic Cancer Lung Cancer, Nonsmall Cell Adenocarcinoma Squamous Cell Carcinoma Large Cell Lung Cancer Thymus Cancer Mesothelioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients diagnosed with a thoracic malignancy

Patients diagnosed with thoracic malignancies will be asked to participate in this cohort.

Health-related quality of life and treatment outcome questionnaires

Intervention Type BEHAVIORAL

Patients who consented to the completion of questionnaires will be invited to complete questionnaires on multiple time points but not more often than once every 3 months. The length of time required for the completion of questionnaires will not exceed 150 minutes a year.

(Tumor) tissue and other biomaterials

Intervention Type GENETIC

Tissue and other biomaterial, such as pleural effusion, is collected from material obtained during a diagnostic procedure or surgical resection. No additional interventional procedures are performed to obtain the material.

Blood samples

Intervention Type PROCEDURE

Blood samples can be withdrawn on multiple time points with a maximum of 10 tubes of 10 ml per year during routine blood withdrawals (or in exceptional cases with an additional blood withdrawal).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Health-related quality of life and treatment outcome questionnaires

Patients who consented to the completion of questionnaires will be invited to complete questionnaires on multiple time points but not more often than once every 3 months. The length of time required for the completion of questionnaires will not exceed 150 minutes a year.

Intervention Type BEHAVIORAL

(Tumor) tissue and other biomaterials

Tissue and other biomaterial, such as pleural effusion, is collected from material obtained during a diagnostic procedure or surgical resection. No additional interventional procedures are performed to obtain the material.

Intervention Type GENETIC

Blood samples

Blood samples can be withdrawn on multiple time points with a maximum of 10 tubes of 10 ml per year during routine blood withdrawals (or in exceptional cases with an additional blood withdrawal).

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years;
* Histo/cytopathological proof of a thoracic malignancy, or a strong suspicion (after imaging and multidisciplinary board);
* Informed consent for longitudinal observational data collection;

Exclusion Criteria

* Mentally challenged patients that are unable to provide conscientious informed consent as determined by the investigator.
* Inability to provide a written or electronic informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No